Jefferies raised its price target on AxoGen, Inc. (NASDAQ:AXGN) to $25.00 from $24.00 on Tuesday, while maintaining a Buy rating on the stock.
The price target increase follows AxoGen’s second-quarter sales results, which exceeded consensus estimates by approximately 8% with double-digit growth across all markets.
Gross margins rebounded quarter-over-quarter after elevated inventory write-offs in the first quarter, surpassing consensus expectations.
AxoGen has raised its fiscal year 2025 sales growth guidance to at least 17% year-over-year, up from its previous forecast of 15-17%, compared to consensus estimates of 16%.
The company’s Avance Biologics License Application (BLA) timelines remain on track, with Jefferies viewing AxoGen as "an underappreciated growth story with good margins and catalyst path at a cheap valuation."
In other recent news, Axogen Inc . reported impressive financial results for the second quarter of 2025. The company exceeded expectations with an adjusted earnings per share (EPS) of $0.12, doubling the anticipated $0.06. Additionally, Axogen’s revenue reached $56.7 million, surpassing the forecasted $52.66 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.